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Abstract
Using medications in the treatment of substance abuse disorders has become as an important part
of available treatment options offered by medical practitioners. In this paper data will be
presented to show the benefits and barriers associated with using several types of medicationassisted treatment to treat opioid use disorder. There are three drugs approved by the FDA for
the treatment of opioid dependence: Buprenorphine, Methadone, and Naltrexone. There has
been limited adoption of pharmacotherapies in the treatment of substance use disorders. In
treatment of addiction, medications are used to reduce the intensity associated with withdrawal
symptoms, reduction of cravings for the substance, and help reduce the chance of continued use
or relapse. This is accomplished by blocking the effects of the drug. Opiate treatment programs
offer medication assisted treatment (MAT) to patients who have been identified with an opiate
use disorder from a qualified professional. Opioid treatment programs offer an array of services.
The purpose of services includes reducing, eliminating, or preventing the use of illicit drugs; as
well as reducing possible illegal action and the increase of communicable diseases including
HIV. The substance abuse and chemical dependency treatment field has been challenged to
implement evidence-based practices. There has recently been a dramatic increase in the number
of interventions for substance use prevention and medication-assisted treatment is one of those
interventions.
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Introduction
The use of medications in the treatment for substance abuse has become a significant part
of the treatment methods available to medical practitioners. The drugs Methadone and
Naltrexone have a relatively long history, but over the last ten years’ medications such as
Buprenorphine, with this that could be called a superior plan of treatment are beginning to be
more noticeable. (Roman, Abraham, & Knudsen, (2011).
The website FDA (2019) outlines the three drugs approved for the treatment of opioid
dependence as: Buprenorphine, Methadone, and Naltrexone. All three treatment options have
proven to be safe and effective when combined with counseling and psychosocial support. Some
individuals believe that people who seek treatment options for Opioid Use Disorders should be
offered access to all three options. Providing access allows providers of services to collaborate
with clients to select a form of treatment suited to their personal needs. Due to the chronic
nature of Opiate Use Disorder, it is recommended that the need for continuing a medicationassisted treatment program be re-evaluated periodically. There is not a maximum recommended
duration of services for maintenance treatment. Some patients may choose to continue treatment
indefinitely.
The concern in the United States with the opioid epidemic continues to increase. New
treatments such as medication-assisted treatment programs have been met with concern by some
and enthusiasm with others. There has been a lack of adoption of these new practices and this
paper will investigate the reasons behind those who believe in the treatment and those who are
against it.
Dangers of Opioids
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Now more than ever, we are hearing of the misuse of prescription opiate pain medication.
Experts of the field acknowledge that the abuse of these of drugs begun more than twenty years
back. Throughout the United States, healthcare experts are giving significantly more
consideration to this issue, and physicians are considering this when recommending opiates as a
treatment option. Before taking them, one should learn as much as possible concerning these
medicines.
How Opiates work:
Opiates are medications that reduce the strength of pain indicators in the patient’s brain. They
also affect the areas of the brain which regulate an individual’s emotion, thus helping to reduce
the effects of pain. This is one of the reasons they can be habit forming.
Opiates include:
Oxycodone (OxyContin, Percocet), Hydrocodone (Vicodin): These potent opiates are the most
commonly used for painful disorders such as broken bones, dental issues, and conditions such as
cancer.
Morphine: This is commonly used after a surgical procedure to lessen pain
Codeine: This is commonly used for mild pain. It can be prescribed for other health issues such
as coughs and severe diarrhea.
Some shocking facts about opioids
The consequences of opiates, involving their habit forming abilities, are a large factor to the
more than 16,600 U.S. deaths from painkillers that happen every year. That is around 45 people a
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day in emergency rooms across the United States. And this does not include the people who
have gone to the emergency room and survived the overdose. (CDC, 2018)
Prescriptions for opiates have risen to 300 percent in the last decade or so. Vicodin and other
hydrocodone-combination painkillers are the most commonly prescribed drugs in the United
States. (CDC, 2018)
The problem of opiate abuse first began in the late 1990s and by the year 2007, deaths from
opiate overdose outstripped deaths from heroin and cocaine in the United States. (CDC, 2018)
In more current years, hundreds of federal, state, and local mediations have been instigated in
reaction to the opiate epidemic. Presently there is a national database that helps healthcare
experts to monitor usage, deaths and other developing data.
When misused, even one large dose can cause severe respiratory failure, which can lead to death.
Nearly one third of females of child bearing age had an opiate prescription filled every year
between the years of 2008 and 2012. Contact with opiates during pregnancy increases the risk of
defects in the unborn child’s brain, heart, spine and abdominal wall. (CDC, 2018)
Sometimes these painkillers do not even relieve the pain. Patients chronically using opiates could
feel worse due to their side effects. Side effects can include: constipation, sedation and
depression. Other patients experience aggravated pain after starting opiates. This is known as
opioid-induced hyperalgesia. (CDC, 2018)
Some numbers on amount of opiates prescribed yearly

After a continual growth of the general national opiate prescribing frequency starting in
the year 2006, the over-all number of prescriptions distributed peaked in the year 2012 to beyond
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255 million and there was a prescription rate of 81.3 prescriptions for every 100 people. (CDC,
2018)

The general nationwide opiate prescription rate dropped in the years 2012 to 2017, and in 2017,
the prescription rate fell to the least it had been in more than 10 years, being 58.7 prescriptions
per 100 people, which is a whole of more than 191 million opiate prescriptions. (CDC, 2018)

Nonetheless, in 2017, prescription rates continued to continue to be higher in specific parts of the
United States. In 16% of counties in the United States, sufficient opiate prescriptions were
prescribed for each person to have one. Whereas the complete opiate prescription rate in 2017
was 58.7 prescriptions per 100 persons, other regions had amounts up to seven times as high as
that. (CDC, 2018)

According to the Substance Abuse and Mental Health Services Administration's National Survey
on Drug Use and Health, a projected 1.9 million people in the United States qualify for abuse
and dependence criteria for prescription pain relievers. Also, the Centers for Disease Control and
Prevention report that yearly, more people die from prescription painkiller overdoses than from
heroin and cocaine combined. (SAMH 2019)

Long term effects of opiate use

A 2012 study by AnGee Baldini, MD, Michael Von Korff, ScD, and Elizabeth H. B. Lin, MD,
MPH found the following information: The reprimand to decrease the abuse of prescription
opiates was publicized by the U.S. Food and Drug Administration (FDA), National Drug Control
Policy, The Drug Enforcement Agency. These organizations recommended physician education
regarding opiate prescriptions. The recent motivation of change was compelled by the rising
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number of deaths and overdoses reported by the Centers for Disease Control and Prevention. The
prevalence of chronic pain has risen to 40% now in the countries contributing, with 10% to 25%
of the populace suffering from substantial deficiency due to their chronic pain. Using opiates to
treat chronic pain that is not related to cancer is becoming more common subsequent to the
endorsements given by numerous pain societies. The commonness of long term opiate use has
steadily risen since the year 1980 with approximately 6-8 million people in the United States
using opiates for the management of long term pain built on the stated use of long-lasting opiate
therapy. With this extensive usage, there is a large amount of material on the consequences of
opiates suitable for use by primary care doctors. This review does consider scientific studies
published within the last six years providing data pertinent to the possible side effects of opiates.

The information collected is accessible in an organ system methodology to enable
training in the practice of primary care doctors. The goals are to improve the doctors’ abilities in
discussing the side effects of opiates with their patients of whom are considering long term use
for long-lasting discomfort, as well as to raise awareness of doctors and users in recognizing
possible side effects that could be caused by the use of the opiate pain killers. (Baldini, Von
Korff, & Lin, 2012)

Method: The research for the data in the reports available in scientific periodicals in the years
2005-2011 was directed utilizing Quality Clinical Guidelines, Medline Agency for Healthcare
Research and Cochrane Database of Systematic Reviews and Evidence Based Reports. A review
was implemented due to the large amount of publications related to the negative effects of
opiates being normally trivial, and the multiplicity of negative effects across the systems

RUNNING HEAD: MEDICATION-ASSISTED TREATMENT

10

prevented a measureable evaluation. The organ systems included were the respiratory, immune,
gastrointestinal, musculoskeletal, cardiovascular, endocrine, and the central nervous system.
Inside each system, it was initially considered articles to meet criteria that included the words
opiate and each organ system in the title, or body of each article. There were 1,974 initially
identified articles, 74 of which incorporated verification of prolonged opiate abuse on each
system that was identified. In the identified articles, there were 43 selected on the significance in
prescribing by primary care doctors. Other articles identified by the experts’ recommendations
and other related bibliographies supplemented the study. (Baldini, Von Korff, & Lin, 2012)

Results: Gastrointestinal System Effects
Constipation was one of the predominant negative effects of long term opiate therapy generally
well-known by doctors and their patients as a negative outcome of opiate use. The
pathophysiology of this progression outcomes from the stimulus of the opiate receptors in the
digestive tract. Multiple studies have reported that up to 45% of patients using opiates experience
constipation, while up to 25% also reported nausea. Constipation related to opiate usage still
remains obstinate to treatment using laxatives and stool softener medications. Constipation
reported had been severe enough that patients had to reduce the dosage of their medicine or stop
opiate use completely. In the starkest examples, opiate abuse has been known to raise the
possibility of bowel obstructions, which could result in being hospitalized and even demise. In
supplement to the constipation and nausea, opiate use could trigger bloating, vomiting, and
abdominal cramps. The risk of intestinal bleeding is comparable to nonsteroidal antiinflammatory (NSAID) medications. (Baldini, Von Korff, & Lin, 2012)
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The negative consequences of these intestinal effects weigh significance for particular attention.
Constipation can be related with other quality of life problems. Studies discovered that up to one
third of constipated opiate users reported psychological suffering and increased frequency of
being depressed related to the controlled patients. Patients with stomach complaints related to
opiate use have considerably more hospital visits and hospital admission rates, longer stays while
admitted in the hospital, and higher rates of primary care doctor visits. The linked damage to
quality of life should be compared to opiate efficiency for their chronic pain. (Baldini, Von
Korff, & Lin, 2012)

Respiratory System Effects
There has been a link between sleep breathing disorders and the use of opiates found in more
current studies. Continuing opiate use is proven to be related to the symptoms of sleep disordered
breathing, ataxic breathing, sleep apnea, hypoxemia, and also retention of carbon dioxide. With
patients that were on opiate therapy for six months or longer, the commonness of mild to severe
sleep disordered breathing has been proven to be up to 75%. Comparing, samples of the
population, sleep disordered breathing is only detected in 3% - 20% of people. In another smaller
study, sleep apnea was discovered in up to 30% of patients using methadone. Also as much as
10% of patients using opiate therapy experience a type of hypoxemia. These adverse results of
opiates seem to happen in a dependent of dose manner. Ataxic breathing was detected in as many
as 92% of patients who were given a morphine dose of 200 mg, 61% of patients taking under
200 mg, and in only 5% of patients that were not taking opiates. While the risk of death from
opiate overdose has been established in other studies, death from sleep disordered breathing does
need more research, as what studies that are available are usually small and contain misleading
samples. (Baldini, Von Korff, & Lin, 2012)
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Respiratory System Depression
There are life threatening side effects of opiate medications such as bradycardia, respiratory
depression, and hypotension, occurring during an opiate overdose. Though this is not completely
comprehended, a physical tolerance to painkillers does not automatically compare to a tolerance
of the results of opiates on the breathing system. Patients who were being prescribed larger doses
of opiates were found to have proficiency in the increased risk of overdose. The estimations of
this danger all differ, nonetheless more current documentation has established an 8.9% increase
in persons using more than 100 milligrams daily, relative to persons receiving opiate treatment of
fewer than 20 milligrams daily. And a 3.7 % rise amongst people using more than 50 milligrams
daily. Among patients prescribed higher opiate dosages, the danger of opiate overdosing can be
projected to be 1.8% for each year of opiate use. Furthermore, 12% of overdoses resulted in
death, proposing a yearly overdose possibility of 2 per 1,000 individuals per year among patients
on high dose opiate treatment. The approximations were even with Centers for Disease Control
and Prevention mortality information related to deaths from opiate overdose. Which are almost
equivalent to car accidents as one of the prominent causes of death of 35–54 year olds. (Baldini,
Von Korff, & Lin, 2012)

Cardiovascular System Effects
A recent analysis amongst elderly people suffering from arthritis discovered that opiate
painkillers were paralleled to NSAID medications such as ibuprofen, opiate therapy was linked
to a 77% increased risk of cardiovascular occurrences such as heart failure. During the initial 30
days, the risk of cardiovascular occurrences was comparable with most opiates. Conversely,
following 180 days of being on codeine, treatment was coupled with up to a 62% upsurge in
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these opposing actions as paralleled to hydrocodone treatment. Another large study examining
health insurance claims showed increased risks of myocardial infarction and cardiovascular
revascularization among patients on opiate therapy relative to people not using opiates. All the
results of opposing cardiovascular properties of opiates could be described by the possible
prejudices in investigation and may need to be repeated. It cannot be presumed that opiates have
lower cardiotoxicity than COX-2 inhibitors in the nonexistence of data supporting this
assumption. (Baldini, Von Korff, & Lin, 2012)

Central Nervous System Effects
A noteworthy problem, especially among elderly users is Opiate neurotoxicity. Dizziness and
sedation are additional properties that could potentially result in unintentional penalties amongst
patients getting indefinite opiate treatment, such as breaks, painful falls, respiratory distress.
Hyperalgesia related to extreme sensitivity to pain has been described in people on opiate
regimens. Also, patients on opiate medications are shown to develop elevated levels of
depression of around 38%. Intriguingly, it has been shown that people on opiates with emotional
illness have a suggestively superior amounts of hospital stays. Associated use of central nervous
system depressants such as barbiturates, and alcohol magnify respiratory depression and can
result in potential apnea. (Baldini, Von Korff, & Lin, 2012)

Musculoskeletal System Effects
One of the important unfavorable effects of opiate painkillers are their relationship with the
elevated possibility for fractures. However, the main reason for this increased risk is not clearly
comprehended, the dominant idea is that opiates do lead to an elevated potential for tumbles
across the central nervous system such as dizziness and decreased alertness. New studies report a
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related risk of breaks at about 1.4 for elderly people who are utilizing opiate medications.
Nonetheless, other approximations have positioned the threat ratio for amplified breakage at
close to 4.9 when associating people using opiates to the age related controls who were
prescribed NSAIDs. While the comparative risk is humble at best, because the rates of fractures
are greater among elderly adults, the total increase in fracture risk is very prominent. In the
population of over age 65-year-old, opiate medications bestowed a risk of 1.6 for fractures. New
studies have found that propoxyphene and morphine greater than 50 mg daily doubled the risk of
fractures in elderly patients, with an annual fracture rate of 9.95%. Also, higher amounts of
opiates communicate to a elevated fracture possibility amongst elderly patients. Another study
uncovered that shorter acting opiates carry higher fracture risk than longer acting opiates inside
the beginning two weeks being used. (Baldini, Von Korff, & Lin, 2012)
Almost all recent studies related the necessity for more examination of the elevated risk for
fractures. Although the number of fractures has gradually decreased, the overall rate for death is
remaining at a high rate of 21.9% per 1 year. Additionally, patients who do survive a related
event more often do not regain their highest quality of life. They more often have declines in
their mental and physical health, and also may require institutional or long term care facilities.
They also have diminished quality adjusted years of life. With respect to other analgesic
therapies, opiates displayed a substantial rise in fractures when paralleled to other medicines like
NSAIDs. (Baldini, Von Korff, & Lin, 2012)

Endocrine System Effects
Long term opiate use has been proved to have an effect on the endocrine system of both the male
and female. The apparatus of these results is supposed to happen through contact with the
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hypothalamic pituitary adrenal axis. Opiate pain killers have been proven to disturb the release of
all the hormones including the anterior pituitary including adrenocorticotropic hormone, growth
hormone, thyroid-stimulating hormone, prolactin, and the lutein-stimulating
hormone. Individuals using long term opiate therapy have been shown to have a hyperactive
functioning hypothalamic-pituitary-adrenal axis supplemented by the decreased functioning of
the hypothalamic-pituitary-gonadal axis. With all of the enteropathies perceived, some of the
weightiest pertain to the decrease of the gonadotropin-releasing hormone. (Baldini, Von Korff, &
Lin, 2012)
The reduction in the gonadotropin hormone can be apparent in male patients as
hypogonadism, recognized as opiate induced androgen deficiency, fatigue, sexual dysfunction,
infertility, and also related to decreased levels of testosterone. The decrease of testosterone is of
special concern because introductory studies suggest the increased risk of metabolic syndrome
and insulin resistance. (Baldini, Von Korff, & Lin, 2012)
The reduced pulsatile release of gonadotropin-releasing hormone and the succeeding reduction in
luteinizing and follicle stimulating hormones can have potential effects in females also. Reduced
quantities of estrogen, low follicle stimulating hormone, and more amplified prolactin could
result in osteoporosis, or other conditions such as galactorrhea. These initial conclusions propose
the need for thoughtfulness when prescribing to people with pre-existing disorders. It is known
that these side effects are usually changeable with discontinuation of medication or by lowering
the dosage. (Baldini, Von Korff, & Lin, 2012)

Immune System Effects
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Many kinds of opiates, such as morphine and fentanyl, are proven to have immunosuppressive
effects. Studies of these effects are challenging to calculate, as precise tools are needed for
additional examination. It is known that these opiates affect the opiate receptors on all of the
immune cells. They could also moderate the immune function subtly through glucocorticoids
discharged by the hypothalamic-pituitary-adrenal axis and norepinephrine that is released by the
sympathetic nervous system. More current studies have exposed an upsurge in pneumonia risk in
elderly people on long term opiate treatment. (Baldini, Von Korff, & Lin, 2012)

How is opiate addiction treated?
Opiate treatment programs and services vary by each provider and by the type of services needed
to effectively address each patient’s needs. According to The Hazelden Betty Ford Foundation,
here are some of the key components of successful opioid addiction treatment. (The Hazelden
Betty Ford Foundation, 2019)
Dialectical Behavioral Therapy (DBT)

This treatment approach emphasizes behavioral change, problem-solving and emotional
regulation, validation, mindfulness and acceptance

Cognitive Behavioral Therapy (CBT)

This form of treatment focuses on exploring patterns of thinking that lead to self-destructive
actions, identifying beliefs that direct thoughts, and learning to modify these patterns of
thinking to improve person’s coping skills
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Acceptance and Commitment Therapy (ACT)

This technique uses mindfulness and behavioral activation to increase psychological
flexibility and the ability to engage in values-based, positive behaviors while experiencing
difficult thoughts, emotions or sensations

Motivational Enhancement and Interviewing

This is a collaborative approach that helps patients identify their benefits with regard to
staying sober, working through difficult issues, and developing skills necessary to
accomplish their goals

Medication-Assisted Therapies (MAT)

Medications are now used to treat substance use disorders related to opioids and alcohol,
helping ease withdrawal symptoms and reduce drug cravings. Use of medication-assisted
treatment for opioid dependence with naltrexone and buprenorphine/naloxone is supported
by scientific research and recommended by the U.S. Department of Health and Human
Services Substance Abuse and Mental Health Services Administration (SAMHSA), National
Institute on Drug Abuse (NIDA), Washington Circle, and the Veterans Administration.

Mental Health Services

More often than not, addiction comes with complicating factors such as depression, anxiety
and trauma. These are also known as co-occurring disorders. With such complex conditions,
the most effective approaches to care integrate treatment for the addiction and the mental
health so that both issues are being addressed at the same time. Services may include
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individual or group therapy, family therapy, diagnostic assessments or medication
management. Each type and frequency of care is determined by initial and ongoing
assessments.

Contingency Management/Motivational Incentives (CM)

Incentive based interventions also known as tangible rewards are used to reinforce positive
behaviors, increase addiction treatment retention and promote abstinence from drug abuse.

Interpersonal Therapy (IPT)

This is a short-term, limited focus treatment for depression and anxiety.

Solution Focused Brief Therapy/Solution Focused Therapy
This is a goal oriented therapy focusing on the individual’s present and future, rather than
past. This is considered goal-oriented therapy.

Mindfulness-Based Cognitive Therapy (MBCT)

This technique is used to help prevent depression relapse; it works especially well for those
suffering from major depressive disorder

Educational Groups and Lectures

This therapy focus on educating people about disorders and developing coping strategies
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Twelve Step Facilitation (TSF)

Originally designed as a system to actively engage patients in abstinence based support
groups such as Alcoholics Anonymous, the interventions today are more widely utilized to
help patients achieve and sustain recovery from both substance use disorders and their cooccurring conditions

Other Therapies

Other treatment approaches may include many other therapies that complement care
programs and services, such as:
• Animal-Assisted
• Relapse

Prevention Skills Group

• Communications
• Recovery
• Stress

Programming

Training

Management Skills Building

Reduction Skills Training

• Yoga
• Spiritual

Care

• Emotional
• Distress

Regulation

Tolerance Skills Training

• Experiential
• Process

Therapy

Focused Group Therapy

19
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(The Hazelden Betty Ford Foundation, 2019)

In this paper we explore Medication assisted treatment, commonly known as MAT.
Evidenced Based-Practices
Research is a systematic investigation involving the interpreting, collecting, and
analyzing of information in a sequential manner for the purpose of increasing an individual’s
understanding of the phenomenon of interest. Each characteristic of interest and all aspects of
the environment where the information resides must be defined clearly in order to be confident in
what we find is real. The process of collecting and organizing the data should be conducted and
reported with the most possible precision. This will allow other researchers to reproduce and
verify the validity of findings. The purpose of research is to inform the profession and enhance
the ability to use best-practice methods (Sheperis, Young, & Daniels, 2017).
Evidence-based programs and practices (EBPPs) are specific techniques and intervention
models that have shown to have beneficial effects on results through arduous evaluations.
Evidence-based practice is a process that brings together expertise from professionals, the top
available research, and input from individuals to identify services demonstrated to achieve
positive outcomes (Family and Health Services Bureau 2006).
Limited topics in opiate treatment have more importance than the importance of
implementing evidence-based programs. There is remarkable consensus among leaders within
the field of addiction treatment about the importance of treatment programs’ willingness to adopt
particular innovations (Roman et al., 2011). Evidence-based practices and research can help
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enhance the quality of treatment for substance use disorders by reducing or eliminating the
ambivalent attitudes towards treatment with medication assisted treatment.
According to the Family and Health Services Bureau (2006), individuals may think the
use of evidence-based programs and practices de-emphasizes decisions based on opinion,
authority, or experience. However, utilizing these programs simply means that the best available
research is identified and combined with other factors for the best results. Most advocates of
evidence-based research programs do not diminish their importance associated with experience.
They believe they should be integrated with experiences and resources which agencies and
practitioners bring to practice. Additionally, numerous funding entities require the agencies to
document outcomes and identify evidence-based practices and programs that have been utilized.
Certain policies have utilized modest recording of the adopted behaviors as the standard
for compliance to new criteria because accomplishment of the goal for enriching treatment
quality through innovation is defined by larger degrees of adoption of behavior by treatment
organizations. However, evidence-based practices cannot be placed in one generic category as a
measure for the quality of treatment because there has been no attention given to longer term
application and the degree to which it really tails after acceptance (Roman et al., 2011).
There is yet to be an accepted typology to categorize evidence-based practices related to
substance use disorder treatment. Yet, there is no doubt that they are not alike in their
likelihoods for application inside opiate treatment agencies. Requirements for change within
organizations regarding the object of evidence-based practices and programs varies widely.
Some implementations flow easily and others can have the potential to cause major disruptions
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in the delivery of treatment within the organization. Some innovations directly affect the client
and others have no direct effect on the client care (Roman et al., 2011).
Medication-assisted treatment in combination with counseling and behavioral therapies
can help individuals sustain recovery. More can be done to facilitate treatment options and
develop additional therapies for individuals suffering with an Opioid Use Disorder diagnosis.
Some clients may choose to continue maintenance indefinitely which is the cause of concern for
some practitioners for fear the client has simply swapped one addiction for another. Others
argue that addiction is considered a disease, so why not use medication to treat and manage that
disease like you would any other.
The contrast between traditional psychosocial and pharmacological advances captures
little. Long-term treatment success is perhaps achieved by facilitating acceptance of medicationassisted treatment programs, implementation of pharmacological treatment, psychosocial
interventions, and multiple psychosocial considerations. Recent empirical effectiveness of
buprenorphine drugs like Suboxone appears to challenge this assumption (Roman et al., 2011).
FDA Approved Drugs for Treatment
FDA-approved buprenorphine products approved for the treatment of opioid dependence
include:
Bunavail (buprenorphine and naloxone) buccal film
Cassipa (buprenorphine and naloxone) sublingual film
Probuphine (buprenorphine) implant for subdermal administration
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Sublocade (buprenorphine extended‐release) injection for subcutaneous use
Suboxone (buprenorphine and naloxone) sublingual film for sublingual or buccal use, or
sublingual tablet.
Subutex (buprenorphine) sublingual tablet
Zubsolv (buprenorphine and naloxone) sublingual tablets
FDA-approved methadone products approved for the treatment of opioid dependence
include:
Dolophine (methadone hydrochloride) tablets
Methadone (methadone hydrochloride) oral concentrate
FDA-approved naltrexone products approved for the treatment of opioid dependence
include:
Vivitrol (naltrexone for extended-release injectable suspension) intramuscular (FDA,
2019).
Suboxone
Suboxone, once thought to be a miracle drug to treat opiate addiction, is actually causing
an epidemic in its own right. Suboxone is a mixture of buprenorphine, a semi-synthetic opioid,
and naloxone, an opiate blocker. Suboxone has become overprescribed by medical professionals
to an uninformed patient population.
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Suboxone was first approved for use in the United States in 2003. Conclusions validate
that the drug was formerly favored by the FDA to be used as a medication to aid opiate
addicted patients with the uncomfortable symptoms associated with withdrawing from opiates.
The use of the suboxone was designed to aid opiate addiction patients in a medical office
setting, to help overcome opiate addiction. Conversely, it seems that many medical practitioners
began to see the commercial profits of Suboxone being used as an opiate maintenance program,
and ignoring the long term effects. For this reason, some patients have been enrolled in a
Suboxone program for multiple years, as many as 10 or more.
Patients were attempting to overcome addictions to powerful narcotics such as heroin and
OxyContin and many doctors offered Suboxone as the answer. However, regardless of the
justifications or rationalizations from many within the medical and addiction treatment field, the
basic premise of a Suboxone maintenance program is trading one illegal drug for a legal drug. It
is saying “take this pill and you’ll be okay” or “take this pill and it will take care of your
addiction.” Basically, patients going into a doctor’s office to find a way to “overcome their
addiction” are years later finding themselves still physically dependent and addicted to a
substance. Suboxone keeps opiate withdrawal symptoms at bay, but does not offer any actual
treatment and clearly does not offer a solution for overcoming addiction. Take the Suboxone
supply away from a person on a Suboxone maintenance program and there is little doubt that
they will turn to heroin or OxyContin or another form of opiate once withdrawal symptoms
begin. This is not the patients fault- they were sold a faulty bill of goods by many of those people
prescribing Suboxone.
Hopefully, a competent and informed doctor will explain that a patient needs treatment
for their psychological and emotional issues as well, and a competent doctor will be informed of
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the physical effects of long term Suboxone use, but the question is how many doctor’s are
uninformed and therefore unable to give this necessary information to their patients? Patients
being prescribed Suboxone were told this prescribed medicine would be the solution to their
problem of drug addiction. In addition to the fact that a patient is still physically dependent on a
substance to function, there are several disturbing effects of Suboxone that are rarely discussed.
Suboxone and Its Side Effects
Since Suboxone is often being prescribed by physicians that are not trained in addiction
medicine and in the treatment of addiction, there are many issues go unobserved and are not
regulated. Suboxone utilized as medication for treatment of opiate detox is first-rate. In the hands
of a properly trained practitioner, Suboxone makes opiate detox significantly more comfortable.
Suboxone is an outstanding treatment in assisting opiate addicts throughout their withdrawal
symptoms. Conversely, the long term use of Suboxone may cause a multitude of medical
problems. Additionally, numerous Suboxone users report getting sober from the Suboxone is
more challenging other opiate medications. Since normal opiate detox lasts 5-7 days Suboxone
may stay in the system for as many as 9 days. Withdrawal from Suboxone may take weeks to
many months and will only bring painful physical systems and possibly more disturbing mental
health problems. Patients often report depression and anxiety. Many report that withdrawing
from the use of Suboxone, may last weeks and even months.
Suboxone in the Long Term, Is it Safe?
Suboxone use in the long term will cause withdrawal symptoms such as: anxiety, nausea
depression, restlessness, sweats, fatigue, joint and muscle pain, insomnia, loss of libido, lack of
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motivation. Opiate withdrawal symptoms normally last about one week, Suboxone withdrawal
may last for some weeks or even months.

Methadone
Methadone has been used for decades to treat people who are addicted to heroin and
narcotic pain medicines. When taken as prescribed, it is safe and effective. It allows people to
recover from their addiction and to reclaim active and meaningful lives. For optimal results,
patients should also participate in a comprehensive medication-assisted treatment (MAT)
program that includes counseling and social support.
Methadone decreases opiate cravings and withdrawing and blocks the effects of illegal
opiates. Methadone may be prescribed as liquid, powder or wafer and is taken once a day.
Methadone is effective in higher doses, particularly for heroin users, helping them stay in
treatment programs longer.
As with all medications used in medication-assisted treatment (MAT), methadone is to be
prescribed as part of a comprehensive treatment plan that includes counseling and participation
in social support programs.
Patients taking methadone to treat opioid addiction must receive the medication under the
supervision of a physician. After a period of stability (based on progress and proven, consistent
compliance with the medication dosage), patients may be allowed to take methadone at home
between program visits. By law, methadone can only be dispensed through an opioid treatment
program (OTP)certified by SAMHSA.
The length of time in methadone treatment varies from person to person. According to
the National Institute on Drug Abuse Publication Principles of Drug Addiction Treatment: A
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Research-Based Guide – 2012 (PDF | 391 KB), the length of methadone treatment should be a
minimum of 12 months. Some patients may require treatment for years. Even if a patient feels
that they are ready to stop methadone treatment, it must be stopped gradually to prevent
withdrawal. Such a decision should be supervised by a doctor.

Naltrexone
Naltrexone, commonly known by its brand name Vivitrol is an antagonist or opiate
blocker medication. Antagonists form an obstruction that blocks opiate particles from connecting
to the opioid receptors. Antagonists attach to opioid receptors, but do not result in the release of
dopamine. They are not addictive and will not result in any type of physical dependence.
Vivitrol blocks opioid receptors in the brain for one month, helping patients prevent
relapse to opioid dependence, following opioid detox. Patients must be opioid-free before
starting Vivitrol.
New study backed by the National Institute on Drug Abuse (NIDA) exposed that the
relapse rates among adults with a history of opiate dependence were lower for patients receiving
extended-release naltrexone than for those receiving treatment as usual (brief counseling and
referrals for community treatment programs). Administered as a monthly injection, Vivitrol is an
FDA-approved sustained-release, opioid antagonist for the prevention of relapse to opioid
dependence. (NIH, 2016)

This study is the initial big randomized trial of naltrexone versus usual care conditions
among adults. The results presented that at 24 weeks (six monthly injections) of extended-release
naltrexone resulted in a considerably lower opioid relapse rate (43 percent to 64 percent)
between the two groups. Furthermore, while there were no overdoses observed in the extended-
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release naltrexone group, there were seven in the usual care group, with three resultants in
deaths. (NIH, 2016)

Opiate Addiction Truth
Many believe opiate addicts are seen as being hopeless by many within the medical field.
The potential for relapse for opiate addicts is so high and the rate of overdose is higher than any
other drugs in addiction treatment. Usually, opiate addicts that seek treatment and succeed at
having some time away from opiates end up using opiates again, and because of the decreased
tolerance this often results in an overdose. Many addicts die from this. For this reason,
medication assisted treatment such as Suboxone or methadone is often used by doctors and
treatment centers as “harm reduction”.
The resulting facts are that these practitioners do not look at an opiate addict as someone
that can ever succeed at sobriety, but more so as a number that they are trying save from being in
the overdose statistics. Such as, “that girl could certainly not get sober so we should try to keep
her from overdosing and dying.” This may seem like a brilliant belief, but here are two main
issues:
This knowledge is underestimating the addict’s willingness and ability to get clean.
Treating with this harm reduction theory instead if offering them complete addiction
treatment seems to be uneducated and shows diminutive understanding of addiction. This may be
true or that, or the doctor is simply looking to cash in on profitable side of medication assisted
treatment to keep someone on maintenance treatment than helping them get clean and sober by
giving them effective addiction treatment.
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Suboxone is the facilitator for this new maintenance treatment model and may actually be
causing more damage than benefits. More addicts than ever are being prescribed Suboxone and
getting less and less real treatment and never improving their quality of life. Regularly they
substitute opiate abuse with another problem, such as with drinking alcohol or by using other
drugs, or engaging in other high risk behaviors. More often many are still suffering with
emotional distress or trauma that has not been resolved. When these persons definitively
understand that the amazing wonder drug Suboxone has manifested into a completely new
addiction and they want to stop use, they will find it more difficult to do than the opiates they
were initially recovering from.
But also, many experienced, educated clinicians that employ Suboxone properly, pair it
with effective treatment and use a complete look at each patient and their individual situations.
There are may be some cases when Suboxone maintenance best or only solution for the patients’
condition. However, these are very few cases. Normally, numerous physicians recommending
Suboxone are doing this without requiring any type of ample treatment. Furthermore, numerous
physicians that recommend Suboxone need less than an appointment and a payment for a person
to receive their suboxone. Many times, after the first visit, the doctor will prescribe the suboxone
after only a short second visit. This definitely should not be comprehensive addiction treatment.
This is absolutely not recovery based therapy in any definition.
Opiate Abuse in Today’s Youth
Abuse of opiates, is one of the most rapidly developing addiction problems in the United
States. In 2016 there were a reported 3.6 percent of pubescents aged from 12 to 17 abusing
opiates. The statistics are doubled among older juveniles and younger adults aged 18 to 25. The
majority of this issue is due to prescribed opiates and not from heroin. (HHS, 2019)
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According to The U.S. Department of Health and Human Services (2019) opioid abuse is
declining. Among high school seniors, past-year misuse of prescription opiates lessened from a
peak of 9.5% in the year 2004 to 3.4% in the year 2018. The misuse of the drug Vicodin reduced
from an all-time high of 10.5% in the year 2003 to 1.7% in the year 2018. The misuse of
OxyContin decreased from 5.5% in the year 2005 to 2.3% in the year 2018. (HHS, 2019)

Additionally, children in 12th grade agree that opiates are more difficult to get access to
than in years past. In the year 2010, 54% of 12th graders agreed that these medications were more
easily obtainable, as paralleled to 32.5% in the year 2018. Overdose is the most serious
significance of any type of drug abuse, especially opiates. Although the number of drug overdose
deaths are still lower in general, the rate of overdose deaths among youth is still on the rise. In
the year 2015, 4,235 young people aged 15 to 24 were declared dead from drug overdoses and
more than half were attributed to opiates. (HHS, 2019)

All adolescents are at risk for misusing opiates. Although, there are a wide range of
factors that can either increase the risk of prescription drug misuse or help protect against it. For
example:

•

Individuals at increased risk of opioid misuse include those with: acute and chronic pain,
physical health problems, or a history of mental illness or other substance use or misuse. Youth
who have witnessed a family member overdose or who have friends who misuse prescription
drugs also are at highest risk. Data shows that almost half of adolescents aged 12 to 17 reported
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misusing prescription pain relievers and reported that they were free or purchased them from a
friend or even a family member. This reported rate is more than half for young adults aged 18 to
25 who reported their misuse of pain relievers. (HHS, 2019)
•

Youth at the lowest risk were those who are committed to getting good grades, and going to
college and those who are educated about the dangers of prescription drug abuse. Furthermore,
young people who have a stronger relationship with their parents and whose parents do not
approve of substance use are also at a lower risk of misuse. (HHS, 2019)

MAT for Youth
Using MAT such as Suboxone can be used in 2 primary ways:

1. As a short course of treatment to reduce the complications of opiate withdrawal.
2. As a longer course of maintenance treatment

Though younger opiate users are at higher risk for overdose and other serious effects,
since teenage users rarely have lengthy use histories, they are not necessarily great candidates for
long-term Suboxone maintenance treatment.

According to a SAMHSA (2018) expert consensus panel, for adolescent opiate dependent users:
1. A short course of Suboxone for detoxification followed by continuing treatment with naltrexone
is the preferred treatment to start with.
2. If, after detox with Suboxone and continuing treatment with naltrexone, relapse occurs, then
Suboxone maintenance treatment becomes more appropriate.
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Opiate Abuse in The Elderly

One population usually overlooked for substance abuse is the elderly many of whom are on these
medications for chronic pain, places them at high risk of abuse. Prescription opiate abuse affects
up to 17% of adults over the age of 60 according to the National Institute on Alcohol Abuse and
Alcoholism (2019). Due to inadequate information, very little data, and rushed office visits,
prescribers, abuse among the elderly often goes unnoticed. This is worsened by the circumstance
that elderly people often have medical or mental disorders that imitate indicators of substance
abuse, such as depression, diabetes, or dementia. (NIAAA,2019)

According to the Office of Alcoholism and Substance Abuse Services, substance abuse
among senior citizens can be categorized into two forms: the “hardy survivor,” or those who
have been abusing substances for numerous years and have reached age 65, and the “late onset”
group, which is those who form addictions later in life. (NIAAA, 2019) Medication assisted
treatment such as methadone can be considered as a viable option for seniors experiencing
prescription opiate abuse or seniors who are experiencing chronic pain.

There are numerous factors that lead to turning to substance abuse later in life. These
could be health correlated problems or life changing traumas that take an emotional toll. These
events may provoke substance-abusing behavior that can result in a total substance abuse.

Possible risk factors for drug addiction in the elderly include:
•

Retirement

•

Death of a family member

•

Death of a spouse, pet or close friend
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•

Loss of income or financial strains

•

Relocation or placement in a nursing home

•

Insomnia

•

Family discord

•

Decline in mental or physical health

(NIAAA, 2019)

Benefits of Medication Assisted Treatment
Benefits of Methadone include:
•

Easy induction

•

Lower medication costs

•

High retention rates

•

Lowers drug use

•

History of successful use in pregnant women
(Williams, 2018)

Benefits of Suboxone include:
•

Minimal overdose risk

•

Flexible dosing

•

Excellent pain control

•

Better outcomes in newborns
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•

Less stigma

•

Injectable forms are being created
(Williams, 2018)

Benefits of Vivitrol include:
•

Relieves cravings

•

No fear of withdrawal symptoms

•

Blocks opiate use of any kind

•

Twice as successful in extended release injectable form
(Williams, 2018)

Disadvantages of Medication Assisted Treatment
The disadvantages of Methadone include:

•

Daily dosing

•

Limited or no access to local programs

•

Risks of combining with other medications

•

Highly stigmatized

•

Can lead to cardiac issues
(Williams, 2018)

The disadvantages of Suboxone include:

•

Risks of painful withdrawal
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•

Street value

•

Stigma

•

Patients can misuse and abuse

•

Requires DEA Waivered clinician
(Williams, 2018)

The disadvantages of Vivitrol include:

•

Hard to find trained providers

•

Insurance issues

•

No pain relief

•

Lowers tolerance

•

Less effective in oral pill form
(Williams, 2018)

Success Rates of MAT- Suboxone

People addicted to prescription painkillers reduce their opioid abuse when given sustained
treatment with the medication buprenorphine plus naloxone (Suboxone), according to research
published in The Archives of General Psychiatry and conducted by the National Institute on
Drug Abuse (NIDA), part of the National Institutes of Health. The study, which was the first
randomized large scale clinical trial using a medication for the treatment of prescription opioid
abuse, also showed that the addition of intensive opioid dependence counseling provided no
added benefit. (NIDA 2007)

35
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"The study suggests that patients addicted to prescription opioid painkillers can be effectively
treated in primary care settings using Suboxone," said NIDA Director Nora D. Volkow, M.D.
"However, once the medication was discontinued, patients had a high rate of relapse — so, more
research is needed to determine how to sustain recovery among patients addicted to opioid
medications." (NIDA 2007)

Pain medications are beneficial when used as prescribed, but they have significant abuse
liability, especially when taken for non-medical reasons. This study examined whether the FDAapproved medication Suboxone could help combat this growing problem. Suboxone is a
combination of buprenorphine to reduce opioid craving plus naloxone, which causes withdrawal
symptoms in someone addicted to opioids if Suboxone were taken by a route other than orally, as
prescribed. This combination was specifically designed to prevent abuse and diversion of
buprenorphine and was one of the first to be eligible for prescribing under the Drug Addiction
Treatment Act, which permits specially trained physicians to prescribe certain FDA approved
medications for the treatment of opioid addiction. (NIDA 2007)

Most studies examining treatments for opioid dependence have been done with heroin-addicted
patients at methadone clinics, so there have been little data on treatment for patients addicted to
prescription painkillers, especially in the offices of primary care doctors. To help address this
issue, NIDA’s Clinical Trials Network launched the Prescription Opioid Addiction Treatment
Study (POATS) in 2007, which took place at 10 treatment sites around the country.

"Despite the tremendous increase in the prevalence of addiction to prescription painkillers, little
research has focused on this patient population," said Roger Weiss, M.D., of Harvard Medical
School, Boston, and the lead author of the study. “This is the first large-scale study to examine
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treatments exclusively for people who were abusing prescription painkiller medications and were
treated with buprenorphine-naloxone, which can be prescribed in a physician's office." (NIDA
2007)

In the study, more than 600 treatment-seeking outpatients addicted to prescription opioids
received Suboxone in combination with brief standard medical management, in which physicians
evaluated treatment effectiveness and recommended abstinence and self-help participation. Half
of the participants also received varying intensities of addiction counseling as provided by
trained substance abuse or mental health professionals. (NIDA 2007)

Results showed that approximately 49 percent of participants reduced prescription painkiller
abuse during extended (at least 12-week) Suboxone treatment. This success rate dropped to 8.6
percent once Suboxone was discontinued. Reductions in prescription painkiller abuse were seen
regardless of whether or not the patient reported suffering chronic pain, and participants who
received intensive addiction counseling did not show better outcomes when compared to those
who did not receive this additional counseling. (NIDA 2007)

Success Rates of MAT- Methadone

Methadone maintenance is more effective in reducing heroin use among addicts
than a 180 -day detoxification program that included an array of counseling
services, a UC San Francisco study has found.

The objective of the study was to compare methadone maintenance-a widely used
but controversial method of weaning heroin addicts off the drug—with an
alternative treatment of psychosocially enriched 180 day methadone assisted
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detoxification. Methadone maintenance resulted in lower heroin use rates and
fewer drug- related HIV risk behaviors, such as sharing needles. The study
results will be published in the March 8 issue of the Journal of the American
Medical Association.
“Methadone maintenance is controversial,” said Sharon Hall, PhD, lead author of
the study and UCSF professor in residence and vice-chair of psychiatry. “People
don’t like it because it is continued provision of an addicting drug. When
people come on methadone maintenance, they may stay on it for several years.
The idea of the study was to do a comparison to find a method that was as
effective but didn’t involve indefinite treatment with an addicting drug.”

Methadone maintenance has been used to treat heroin addiction since 1964, Hall
said. Heroin is a short- acting opiate, Hall explained, meaning it produces a
high and a withdrawal effect rapidly. Methadone is a slower acting—and
legal—opiate. It works by stabilizing heroin users so that they do not have a
heroin -induced euphoria or suffer from severe withdrawal symptoms.

The study enrolled 179 participants who were assessed monthly for a year. A
urine specimen was collected each time.

Those in the methadone maintenance part of the study received stable doses of
methadone. Participants also attended one hour per week of substance abuse
group therapy for the first six months and one hour per month of individual
therapy.
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Those in the 180 -day detoxification program received 120 days of methadone
treatment, followed by 60 days of methadone dose reduction until they were no
longer taking methadone. They also received a host of drug counseling services.
During the first six months, participants were required to attend two hours per
week of substance abuse group therapy, one hour per week of cocaine group
therapy if they were found to also be addicted to that drug, and a series of
one- hour substance abuse education classes held weekly. They also attended
weekly individual therapy sessions. During the last seven months of the study,
participants were offered aftercare treatment that included weekly individual
and group psychotherapy and liaison services with the criminal justice system,
medical clinics and social service agencies.

Methadone maintenance was found to retain more patients and be more effective
in decreasing heroin use, though use was still high in both groups. Also, the
study found that those addicted to cocaine were more likely to drop out of the
180-day program than the methadone maintenance program.
“I think the results came out the way they did because heroin is a very
addicting drug and we need pharmacological tools at this point to fight that
addiction,” Hall said. “It’s not enough to just provide psychosocial services
when we lose methadone. There are two ways the field could change. One is to
develop more sophisticated pharmacological treatments for heroin addiction that
have less addiction potential. Another thing we need to think about is
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developing psychosocial interventions targeting what methadone patients need
like legal and vocational services.”

Hall added that one of the reasons the counseling services offered as part of
the 180- day detoxification program did not lower heroin use might be because
they were too general.
“The other thing this study points out is that a long time ago methadone
maintenance clinics had many more services than they do now,” she said. “And
perhaps that’s one of the reasons the 180 day detoxification didn’t work. The
services were limited in scope. We didn’t have legal or vocational services or
family therapy. Many methadone programs have lost funding for these types of
services and we have yet to see what a methadone program looks like that has
them.”

Success Rates of MAT- Vivitrol

Recent research indicates that extended release naltrexone also known as Vivitrol, resulted in a
lower rate of opiate relapse when paralleled to the usual treatment in a mainly male and minority
people. The study participants were on an outpatient basis, voluntary participants with criminal
justice involvement and opioid abstinence.

The National Institute on Drug Abuse, a government organization that is part of the National
Institutes of Health (NIH) co-sponsored a large, multisite, randomized trial to test the
effectiveness of extended-release naltrexone among community-dwelling criminal justice
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offenders who were at high risk for opioid relapse and other related adverse outcomes. The cosponsor was Alkermes, the manufacturer of the product.
The report can be accessed at: Lee JD et al. “Extended-release naltrexone to prevent opioid
relapse in criminal justice offenders.” N Eng J Med 2016; 374:1232-42.

The authors stated that opioid dependence disproportionately affects U.S. criminal justice system
populations. Relapse back to drug addiction and opioid overdose deaths occur at higher rates
after release from incarceration.

METHODS
The trial involved five sites, all independently funded and using a common collaborative
protocol. The sites were:

1. University of Pennsylvania
2. New York University School of Medicine
3. Bellevue Hospital Center
4. Brown University
5. Rhode Island Hospital
6. Columbia University
7. Friends Research Institute

The trial was open label without placebo control. It evaluated a 24-week course of Vivitrol
compared with the usual treatment, such as counseling for community treatment programs for the
prevention of opiate relapse among adults who had a history of opiate dependence and a
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preference for opiate free rather than medication assisted treatment programs, and who were
sober from opiates at the time of the study. (Lee JD et al, 2016)

The main result was the time to an opiate relapse event, being outlined as 10 days or more of
opiate use in 28 days as evaluated by self-report and by urine drug screens obtained every two
weeks. A positive urine screen was processed as 5 days of opiate use. (Lee JD et al, 2016)

Secondary results of attention include rates of alcohol and noon opiate drugs, risk of HIV,
arrests, incarcerations, and overdose. (Lee JD et al, 2016)

RECRUITMENT
The study engaged adult volunteers who were criminal offenders with a background of opiate
use. It includes 153 participants that were allotted to Vivitrol and 155 that were allocated to the
usual rehab treatment groups. (Lee JD et al, 2016)

The average age of all the subjects was 44 years old, with 85% of participants being male. All
participants reported their history of opiate use, and 34% reported using heroin or another opiate
in the 30 days prior. (Lee JD et al, 2016)

Doctors and nurses dispensed Vivitrol via injection. Vivitrol was administered at 380 milligrams
every four weeks, intramuscularly. Participants in the opposing treatment group received similar
counseling, education on the prevention of relapse, overdose, and encouragement for community
participation. (Lee JD et al, 2016)
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Appointments followed screening, every two weeks for a 24-week treatment phase. After
treatment follow up appointments were scheduled at weeks 27, 52, and week 78 including urine
drug screens and patient reporting of opiate and any other drug use. (Lee JD et al, 2016)

STUDY RESULTS

1. During the 24-week treatment phase, the amount of time to relapse was considerably
lengthier at 10.5 weeks in the Vivitrol group than was in the other treatment group at 5.0
weeks.
2. Relapse was identified in 66 patients in the Vivitrol group, as paralleled to 99 in the usual
treatment group.
3. The was a 74% rate of negative urine drug screens throughout the 24-week treatment and
56% in the usual treatment group. At one year after treatment, rates of opiate negative
urine drug screens were equivalent at 46% in both groups.

(Lee JD et al, 2016)

SUMMARY
The study indicated that Vivitrol ensued in a lower rate of opiate relapse than the rate was with
usual treatment. The study did not compare Vivitrol with the regular of opiate agonist that is in
medication assisted treatment.

Suboxone Withdrawal
Throughout withdrawal, the body is performing a lot of exertion. Therefore, one can
anticipate to go through physical symptoms as you suffer from the detox process. Also, a
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person’s mental health issues may emerge. Some detox and treatment facilities offer expert
assistance in handling Suboxone withdrawal symptoms. Adequate treatment centers aim to make
your detox as easy as is possible. Some of the most common physical symptoms of detox are:
•

Hot and Cold episodes

•

Skin Irregularities

•

Fatigue/Tiredness

•

Muscle Pain and Discomfort

•

Cravings for drugs

•

Sweating

•

Nausea

•

Vomiting

•

Loss of Appetite

•

Diarrhea

•

Insomnia

(Nova 2018)

The usual symptoms of detox are:

•

Irritability

•

Depression

•

Suicidality

•

Anxiety
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In addition to depression and anxiety, withdrawal may trigger dormant mental health issues to
ascent. Such as, when a female is using Suboxone maintenance for 10 years because it helps her
thoughts of irritation and void. While detoxing from the Suboxone, she be reminded of these
feelings without the numbing effects of Suboxone. Perhaps she is struggling with a personality
disorder for numerous years without any idea about her diagnosis. These thoughts could be
disturbing, if she has never sought help from a professional who is able postulate material and
education about the motives following these feelings. (Nova 2018)

Suboxone Withdrawal Timeline

Paralleled with other opiates, Suboxone does take more time to affect your body and will remain
effective for a longer period. The time connected with opiate withdrawal is different for
everyone. Since Suboxone is long acting, the symptoms of withdrawal will not surface as fast as
they will when with drawling from other opiates. This will make withdrawal from Suboxone
more challenging. (Nova 2018)

Withdrawing from Suboxone will neither take place all at once or struggle on endlessly. It is
more like a many step procedure. The following timeline indicates when symptoms cultivate
during the detox progression. These times may differ for everyone, contingent on their
distinctive body chemistry. (Nova 2018)
•

Days 1 – 3: Physical indicators begin to appear within 12 hours after the last use of
Suboxone. Muscle pain, nausea and diarrhea are common.

•

Days 4 – 7: Patients may suffer from insomnia as the system eradicates the Suboxone.
Anxiety and irritability are common at this stage.
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•

Weeks 2 – 4: After week one, many people become depressed.

•

Month 2+: Relapse prevention is critical at this stage. Cravings for Suboxone may happen
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years after last use of the drug.

(Nova 2018)

Coping with Suboxone Withdrawal Symptoms

There are many approaches to assist with suboxone withdrawal. Some may be treated at home,
while others may only be accessible in a medical detox program. Counselors are able to assist,
classify and survive any emotions that may be felt during withdrawing. Physicians that have
knowledge of addiction know how to treat Suboxone withdrawal, and can help you towards the
best treatment and medications. Persons should involve themselves in some of these healthy
habits:
•

Exercise

•

Eating a balanced diet

•

Hydration

•
•

Social Interaction
Fun Activities

Whether at home or in a medical detox program, patients could profit from using some over the
counter medication. Some common medications that may help cope with Suboxone withdrawal
include:

•

Over the counter painkillers such as Tylenol
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•

Anti-nausea medications

•

Stomach settling remedies such as Sprite or Ginger Ale

•

Antacids

•

Anti-diarrheal medications

•

Multivitamins
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(Nova 2018)

Methadone Withdrawal
Symptoms of methadone withdrawal, typically start to appear within 24-36 hours after your last
dosage of the medication. The detox process is supervised by a physician. The duration of the
process varies for every person, and it could last from 2-3 weeks up to 6 months.

You may be withdrawing within the first 30 hours that you stop taking methadone, if you
experience:

•

tiredness

•

anxiety

•

restlessness

•

sweating

•

watery eyes

•

runny nose
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yawning

•

trouble sleeping
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In the beginning withdrawal symptoms may feel like the flu. Unlike with the flu, withdrawal
symptoms can remain severe for several days. Symptoms may worsen after three days.
Including:

•

muscle aches and pains

•

goosebumps

•

severe nausea

•

vomiting

•

cramps

•

diarrhea

•

depression

•

drug cravings

The symptoms will be at their peak during the first week. Some symptoms can last longer
than a week. These include low energy, anxiety, insomnia, and depression. Withdrawal can cause
so much discomfort that the risk of returning to the use of other opiates is very high.
Consequently, some people discuss remaining on methadone but at a lower dose. Once a person
becomes more stable at a lower dose, another attempt to detox can be discussed. (Harris, 2000)

MAT During Pregnancy
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The American College of Obstetricians and Gynecologists (ACOG) acknowledges that medically
supervised withdrawal can be considered an option under the care of a doctor that is experienced
in perinatal addiction medicine and with the consent of the mother if she is not willing to begin
MAT. (ACOG, 2017)
“Concern about medication-assisted treatment must be weighed against the negative effects of
ongoing misuse of opioids, which can be much more detrimental to mom and baby,” said lead
Committee Opinion author, Maria Mascola, M.D. “Medication-assisted treatment improves
adherence to prenatal care and addiction treatment programs and has been shown to reduce the
risk of pregnancy complications. And while neonatal abstinence syndrome is often seen in
infants who have been exposed prenatally to opioids, it is important to remember that it is an
expected and treatable condition that has not been found to have any significant effect on
cognitive development.” (ACOG, 2017)
“Opioid Use and Opioid Use Disorder in Pregnancy,” provides an up-to-date summary of
treatment options, like methadone and suboxone. This will allow providers to offer better care
for pregnant mothers suffering from opioid use disorder. ACOG recommends that screening for
the mother’s opiate use take place during the first prenatal care visit. Verbal screening is
preferred over urine testing for initial screening because it allows for a more complete
assessment of the mother’s opiate use disorder providing opportunity for conversation that may
encourage lifestyle changes. Urine drug testing may also be used as an adjunct to screening, but
does not detect all substances and can produce false-positives. (ACOG, 2017)
“The postpartum period is already a vulnerable time for new moms, in general, as they face the
stresses of sleep deprivation, caring for a newborn, and possibly symptoms of postpartum
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depression,” said Mascola. “Women with opioid use disorder are dealing with all those things in
addition to the challenges of their addiction, which—without treatment and support—can often
lead to relapse. These guidelines are meant to help ob-gyns assert themselves in the care of their
patients, so that they can make a lasting difference in their lives.” (ACOG, 2017)
Conclusion
The use of medications to treat substance use disorders has emerged as a significant part
of the treatment methods available to medical practitioners. The data in this paper has been
presented to show the benefits and barriers associated with using several types of medicationassisted treatment to treat opiate use. Providing an overview including the pros and cons of the
three drugs approved by the FDA for the treatment of opioid dependence: Buprenorphine,
Methadone, and Naltrexone. In treatment of addiction, medications are used to reduce the
intensity associated with withdrawal symptoms, reduction of cravings for the substance, and help
reduce the chance of continued use or relapse.
Opioid treatment programs provide medication-assisted treatment to individuals who
have been diagnosed with an opioid use disorder from a qualified professional. Opioid treatment
programs offer an array of services. The purpose of their services include reducing, eliminating,
or preventing the use of illicit drugs; as well as reducing potential criminal activity and the
spread of infectious diseases. The substance abuse treatment field has been challenged to
implement evidence-based practices. There has recently been a dramatic increase in the number
of interventions for substance use prevention and medication-assisted treatment is one of those
interventions.
All three of these treatment options have been proven to be safe and effective when
combined with counseling and psychosocial support. Some individuals believe that people who
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seek treatment options for Opioid Use Disorders should be offered access to all three of these
options. Providing access to these options allows providers of services to collaborate with
clients to select a form of treatment suited to their personal needs.
Due to the chronic nature of Opioid Use Disorder, it is recommended that the need for
continuing a medication-assisted treatment program be re-evaluated periodically. There is not a
maximum recommended duration of services for maintenance treatment. Some patients may
choose to continue treatment indefinitely. All benefits and disadvantages should be considered
by patients and their doctor when considering a treatment option best suited and personalized to
each individual’s needs.
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